Author

K.-Y. A. Huang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:host-pathogen & immune response· 5 Organism:human· 5 Research Focus:cell type annotation· 3 Assay:proteomics· 3 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

P. Rijal· 5 shared A. Townsend· 4 shared C.-P. Chen· 3 shared C.-Y. Cheng· 3 shared L. Schimanski· 3 shared S.-H. Cheng· 3 shared S.-R. Shih· 3 shared T. K. Tan· 3 shared

Activity by Year

2017-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

P. Rijal

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Antigenic characterisation of human monoclonal antibodies for therapeutic use against H7N9 avian influenza virus

P. Chang, D. Lukosaityte, J. E. Sealy, P. Rijal, J.-R. Sadeyen, S. Bhat, S. Crossley, R. Daines, K.-Y. A. Huang, A. Townsend, M. Iqbal

This study characterizes human monoclonal antibodies against H7N9 avian influenza virus, identifies key epitopes, and evaluates escape mutants' impact on viral fitness and immune evasion.

bioRxiv · Sep 16, 2022 · PreprintMicrobiology

Anti-spike antibody response to natural infection with SARS-CoV-2 and its activity against emerging variants

C.-P. Chen, K.-Y. A. Huang, S.-R. Shih, Y.-C. Lin, C.-Y. Cheng, Y.-C. Huang, T.-Y. Lin, S.-H. Cheng

This study examines spike-specific antibody responses in SARS-CoV-2 natural infections, showing waning immunity over 11 months and reduced activity against emerging variants like Beta and Omicron.

bioRxiv · Mar 7, 2022Immunology

The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells

X. Zhuang, S. Tsukuda, F. Wrensch, P. A. Wing, M. Schilling, J. M. Harris, H. Borrmann, S. B. Morgan, J. L. Cane, L. Mailly, N. Thakur, C. Conceicao, H. Sanghani, L. Heydmann, C. Bach, , J. A. McKeating

This study shows BMAL1 regulates ACE2 expression and SARS-CoV-2 entry in lung epithelial cells, with SR9009 reducing viral replication through circadian mechanisms.

bioRxiv · Mar 20, 2021Microbiology

Plasmablast-derived antibody response to acute SARS-CoV-2 infection in humans

K.-Y. A. Huang, T. Tan, T.-H. Chen, C.-G. Huang, R. Harvey, S. Hussain, C.-P. Chen, A. Harding, J. Gilbert-Jaramillo, X. Liu, M. Knight, L. Schimanski, S.-R. Shih, Y.-C. Lin, C.-Y. Cheng, , A. Townsend

This study analyzes plasmablast-derived antibodies in three COVID-19 patients, identifying neutralizing antibodies and cross-reactivity with other betacoronaviruses.

bioRxiv · Aug 28, 2020 · PreprintMicrobiology

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

D. Zhou, H. M. E. Duyvesteyn, C.-P. Chen, C.-G. Huang, T.-H. Chen, S.-R. Shih, Y.-C. Lin, C.-Y. Cheng, S.-H. Cheng, Y.-C. Huang, T.-Y. Lin, C. Ma, J. Huo, L. Carrique, T. Malinauskas, , K.-Y. A. Huang

This paper identifies an antibody, EY6A, from a convalescent patient that neutralizes SARS-CoV-2 and cross-reacts with SARS-CoV-1 by binding a conserved epitope on the Spike protein.

bioRxiv · Jun 12, 2020Microbiology

Broadly inhibiting anti-neuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans

P. Rijal, B. B. Wang, T. K. Tan, L. Schimanski, P. Janesch, T. Dong, J. M. McCauley, R. S. Daniels, A. Townsend, K.-Y. A. Huang

This study identifies broadly reactive human monoclonal antibodies against N1 neuraminidase from vaccination and H7N9 infection, showing cross-inhibition of diverse N1 NAs and protective efficacy in mice.

bioRxiv · Jun 26, 2019Immunology

A single cycle influenza virus coated in H7 hemagglutinin provides heterotypic protection and neutralising antibody responses to both glycoproteins.

T. J. Powell, P. Rijal, R. M. McEwen-Smith, H. Byun, M. Hardwick, L. M. Schimanski, K.-Y. A. Huang, R. S. Daniels, A. R. M. Townsend

This study shows that a single-cycle influenza virus coated with H7 hemagglutinin induces heterotypic protection and neutralizing antibodies against multiple H7 strains.

bioRxiv · Nov 27, 2017Immunology